Companies /Healthcare

Abbott Laboratories

NYSE: ABT Medical Devices
$111.67
▼ $2.43 (−2.13%) today
Markets open · 3:32pm ET

Q1 2025 Earnings

Reported Apr 16, 2025, 7:36am ET · SEC source
$1.09
Beat +1.75%
EPS · est. $1.07
$10.4B
Miss −0.57%
Revenue · est. $10.4B
−8.7%
Trailing market
ABT vs S&P since report
6 quarters
Consecutive EPS beats

Market Reaction

% change · around the report
−3%0+3%+6%Apr 16Apr 17report 7:36am ETearnings−1.0%+5.0%
−3%0+3%+6%Apr 16Apr 17earnings−1.0%+5.0%
ABT +5.0%S&P 500 −1.0%
−3%0+3%+6%Apr 16Apr 17report 7:36am ETearnings−1.5%+5.0%
−3%0+3%+6%Apr 16Apr 17earnings−1.5%+5.0%
ABT +5.0%NASDAQ −1.5%
−3%0+3%+6%Apr 15Apr 24report 7:36am ETearnings+0.4%+2.8%
−3%0+3%+6%Apr 15Apr 24earnings+0.4%+2.8%
ABT +2.8%S&P 500 +0.4%
−4%0+4%Apr 15Apr 24report 7:36am ETearnings+0.8%+2.8%
−4%0+4%Apr 15Apr 24earnings+0.8%+2.8%
ABT +2.8%NASDAQ +0.8%
+2.76%
Day of report
+0.99%
Next session
−0.25%
One week
+4.51%
30 days

S&P 500 over the same 30 days: +13.16%.

Did ABT Beat Earnings? Q1 2025 Results

Abbott Laboratories posted a mixed but largely encouraging first quarter of 2025, beating Wall Street's profit expectations while falling just short on revenue. Adjusted diluted EPS came in at $1.09, clearing the $1.07 consensus estimate by 1.75%, while reported sales of $10.36 billion grew 4.0% year over year but trailed the $10.42 billion consensus by 0.57%. The real engine behind the quarter was Medical Devices, where 9.9% reported sales growth to $4.89 billion was led by FreeStyle Libre continuous glucose monitor sales surging 18.3% to $1.70 billion, helping offset a weak Diagnostics segment dragged down by sharply lower COVID-19 testing revenue. Despite acknowledging tariff headwinds in the hundreds of millions of dollars, a challenge shared across the broader medtech sector, Abbott reaffirmed its full-year guidance for organic sales growth of 7.5% to 8.5% and adjusted diluted EPS of $5.05 to $5.25, with second-quarter adjusted EPS projected at $1.23 to $1.27, signaling management's confidence in its diversified global manufacturing footprint.

Key Takeaways
  • Diabetes Care continuous glucose monitors grew 21.6% organically, reaching $1.7 billion in quarterly sales
  • Medical Devices segment led growth with 12.6% organic sales increase
  • Strong U.S. sales growth of 8.4% on a reported basis
  • Adult Nutrition organic growth of 8.7% driven by Ensure and Glucerna
  • Adjusted gross margin expanded 140 basis points to 57.1%
  • Adjusted operating margin improved 130 basis points to 21.0%

“Once again, Abbott's diversified business model delivered top-tier sales and EPS growth. It is this diversification and execution that allows Abbott to navigate through periods of uncertainty and continually deliver sustainable growth.”

Abbott Laboratories CEO, on the earnings call

Forward Guidance & Outlook

Abbott reaffirmed all previously provided full-year 2025 financial guidance: organic sales growth of 7.5% to 8.5%, adjusted operating margin of 23.5% to 24.0% of sales, and full-year 2025 adjusted diluted EPS of $5.05 to $5.25. For Q2 2025, the company projects adjusted diluted EPS of $1.23 to $1.27.

ABT YoY Financials

Q1 2025 vs Q1 2024 · SEC filings Q1 2024 Q1 2025
$0$3.0B$6.0B$9.0B$10.0B$10.4BRevenue$5.0B$5.5BGross Profit$1.4B$1.7BOperating Income$1.2B$1.3BNet Income
$0$3.0B$6.0B$9.0BRevenueGross ProfitOperating IncomeNet Income

ABT Revenue by Segment

Medical Devices$4.9B+9.9%
Diagnostics$2.1B−7.2%
Nutrition$2.1B+3.8%
Continuous Glucose Monitors
Diabetes Care$1.8B+16.5%
Established Pharmaceuticals$1.3B+2.7%
Core Laboratory Diagnostics$1.2B−2.3%
Adult Nutrition$1.1B+4.4%

ABT Revenue by Geography

Rest of World$6.2B+1.2%
United States$4.2B+8.4%

Figures from SEC filings and company reports. Not investment advice.